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Opinion Statement
Interest in the negative symptoms of schizophrenia has increased rapidly over the last
several decades, paralleling a growing interest in functional, in addition to clinical,
recovery, and evidence underscoring the importance negative symptoms play in the
former. Efforts continue to better define and measure negative symptoms, distinguish
their impact from that of other symptom domains, and establish effective treatments as
well as trials to assess these. Multiple interventions have been the subject of investiga-
tion, to date, including numerous pharmacological strategies, brain stimulation, and non-
somatic approaches. Level and quality of evidence vary considerably, but to this point, no
specific treatment can be recommended. This is particularly problematic for individuals
burdened with negative symptoms in the face of mild or absent positive symptoms.
Presently, clinicians will sometimes turn to interventions that are seen as more Bbenign^
and in line with routine clinical practice. Strategies include use of atypical antipsychotics,
ensuring the lowest possible antipsychotic dose that maintains control of positive
symptoms (this can involve a shift from antipsychotic polypharmacy to monotherapy),
possibly an antidepressant trial (given diagnostic uncertainty and the frequent use of
these drugs in schizophrenia), and non-somatic interventions (e.g., cognitive behavioral
therapy, CBT). The array and diversity of strategies currently under investigation highlight
the lack of evidence-based treatments and our limited understanding regarding negative
symptoms underlying etiology and pathophysiology. Their onset, which can precede the
first psychotic break, also means that treatments are delayed. From this perspective,
identification of biomarkers and/or endophenotypes permitting earlier diagnosis and
intervention may serve to improve treatment efficacy as well as outcomes.
Introduction
Paralleling the advent of the second generation or
Batypical^ antipsychotics (SGAs) in the 1990s has
been several important shifts in how schizophrenia
is conceptualized. First, it has transitioned from an
illness defined by psychosis to one reflecting mul-
tiple symptom domains. Interest in negative symp-
toms had been generated by work through the
1980s, but the picture broadened to include, in
particular, cognitive symptoms. Second, discussions
regarding outcome began to firmly embrace the
notion of functional versus clinical recovery, the
latter historically enmeshed in resolution of posi-
tive symptoms (e.g., hallucinations, delusions). The
third shift related to antipsychotics themselves. Ear-
ly evidence was seen as indicating that the newer
drugs, with their different pharmacology, could ef-
fectively treat these other domains, giving rise to
the notion that they were much more than anti-
psychosis agents.
With over two decades of clinical experience involv-
ing these newer drugs now behind us, there have been
further changes in thinking. Enthusiasm regarding the
clinical benefits of SGAs for symptoms beyond psycho-
sis has been tempered considerably based on accumu-
lated evidence [1]. At the same time, the relevance of
both negative and cognitive symptoms in terms of func-
tional recovery [2] has become central to rapidly
expanding efforts focused on: (a) better understanding
these domains and (b) establishing effective treatments.
Indeed, it is not uncommon to see new treatments
evaluated on both domains. However, the focus here
will be negative symptoms, an updated appraisal of
somatic treatments over the last several years, and an
overview of challenges and opportunities as we move
forward. The gold standard will be meta-analyses where
negative symptoms have been the primary outcome,
followed by more global meta-analyses and recent ran-
domized controlled trials (RCTs).
Negative symptoms
Central to the work arising out of the 1980s was the distinction between
primary (i.e., deficit) and secondary negative symptoms [3], although clinically
they can be indistinguishable. More recently, the National Institute of Mental
Health (NIMH)Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS) turned its attention to negative symptoms. From a
treatment perspective, it is noteworthy that the MATRICS consensus statement
makes reference to persistent negative symptoms and indicates the distinction
between primary and secondary negative symptoms is not essential [4]. In
addition, the following features are identified: affective flattening, alogia,
avolition, asociality, and anhedonia [4, 5]. Factor analyses have isolated two
separate but related subdomains, diminished expression (e.g., affective flatten-
ing), and amotivation (e.g., avolition/apathy) [6].
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While debate continues regarding the interrelationship and contribution of
negative versus cognitive (both social cognition and neurocognition) symptoms
to functional impairment, it is clear that their impact is substantial. Resolution of
positive symptoms, even in the early stages of schizophrenia, does not necessarily
translate to functional recovery; figures suggest that full functional/social recovery
occurs in less than 15 % of individuals with schizophrenia, with negative symp-
toms playing a significant role [7]. To this last point, work focusing on the
prodrome of schizophrenia indicates that deficit symptoms and cognitive im-
pairment are evident by the time of the first psychotic break [8, 9], while enduring
primary negative symptoms have been identified in approximately 25–30 % of
individuals with chronic schizophrenia [10].
Treatment
The very nature of negative symptoms has implications regarding pathophysi-
ology and treatment. Whereas positive symptoms are framed in the context of
excess activity (e.g., hyperdopaminergia), negative symptoms, at least histori-
cally, have been conceptualized as reflecting a loss of functioning [11]. This
position was central to the early work distinguishing positive and negative
symptoms, where negative symptoms were associated with structural CNS
changes. As a result, it was postulated that these features would not be amena-
ble to pharmacotherapy in the same fashion as positive symptoms [12]. This
said, how negative symptoms are conceptualized has shifted and numerous
lines of investigation have been undertaken based on the notion that somatic as
well as non-somatic interventions may well effect improvement in the so-called
primary negative symptoms.
The level of interest and enthusiasm are reflected in the number of
reviews on this topic in just the last 2 years, with a cluster of these,
including a recent meta-analysis, specifically addressing treatment [13,
14, 15••, 16–18]. This article follows the format of at least some of
these recent reviews, summarizing and updating the research according
to psychiatric medication class (antipsychotics, antidepressants, CNS
stimulants, anticonvulsants) or highlighted site/mechanism of action
(glutamate, acetylcholine, serotonin, sex hormones, inflammation-im-
munology). Brain stimulation is also reviewed, although non-somatic
treatments are not; the reader is referred to several of the aforemen-
tioned reviews for such information [16, 18]. Finally, it is important to
highlight the fact that these different interventions are, as a rule, carried
out in the face of concomitant antipsychotic treatment, the exception
being trials involving newer antipsychotics.
Antipsychotics
The notion that pharmacological treatment could favorably influence negative
symptoms gained its foothold in the seminal work in the 1980s positioning
clozapine as unique amongst antipsychotics in treatment-resistant schizophre-
nia (TRS). The so-called atypical antipsychotics that followed thereafter have
been seen as sharing this same feature, including those more recently being
investigated that highlight newer mechanisms of action [19]. Further to this last
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point, different theories have been posited to account for atypicality, including
serotonin 5-HT2/dopamine D2 antagonism and fast dissociation from the D2
receptor; more recently, a third generation of antipsychotics has been desig-
nated, with aripiprazole the prototype, characterized by partial dopamine
agonist properties [20]. While studies continue to compare newer antipsy-
chotics, findings do not support a significant difference between atypical anti-
psychotics in the treatment of negative symptoms [21–23]. Evidence, to date,
including several recent meta-analyses [15••, 21], aligns with other earlier
studies indicating: (a) the newer antipsychotics are not superior to their con-
ventional counterparts in the treatment of negative symptoms and (b) the effect
in either case is modest.
Antidepressants
Notwithstanding the challenges in distinguishing negative and depressive
symptoms clinically, an extensive body of literature has accumulated on the
efficacy of antidepressants in the treatment of negative symptoms. This has
generated a number of meta-analyses addressing this topic, some of which look
beyond antidepressants as a class to specific agents and/or groups categorized
by mechanism of action. Two earlier meta-analyses provided equivocal evi-
dence [24] and a lack of support [25], respectively, while the most recent report
has supported some evidence of benefits that differs between agents [26]. A
commentary on the collective work concluded that the evidence is not strong
enough to support their use [27], although trials continue. For example, a recent
12-week placebo-controlled study evaluating buproprion, a dopamine and
norepinephrine reuptake inhibitor as well as nicotine receptor antagonist, failed
to identify clinical benefits [28]. In contrast, a 12-week RCT comparing
reboxetine, a norepinephrine inhibitor (NRI), versus placebo reported a robust
effect size in the reboxetine-treated group, although, notably, all subjects in this
study were chronic and being treated with haloperidol as the antipsychotic [29].
A recently published meta-analysis looking only at mirtazapine, a noradrener-
gic and specific serotonergic antidepressant, concluded it demonstrates benefits
in the treatment of negative symptoms, but trials included those where negative
symptoms were not the primary outcome [30].
CNS stimulants
Historically, such medications have been seen as contraindicated in
individuals with psychosis because of risk of positive symptoms being
induced or aggravated. Indeed, for a period of time, such drugs were
employed as a challenge to establish risk of relapse [31]. The presence
of concomitant antipsychotic treatment seems critical to this argument;
for example, clinical data involving childhood schizophrenia and co-
morbid attention deficit disorder, where individuals received both anti-
psychotics and psychostimulants, indicated that such a combination was
not associated with increased risk of psychosis [32]. The growing focus
regarding negative symptoms and their treatment has renewed interest in
this class of medications, and a recent review of the topic suggested
evidence of benefits, adding that risk is reduced in clinically stable
individuals with minimal positive symptoms and concomitant antipsy-
chotic therapy [33]. While earlier trials employed drugs used routinely in
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attention deficit hyperactivity disorder (ADHD) (e.g., methylphenidate,
d-amphetamine), there has been a shift more recently to trials with
drugs used in the treatment of excessive sedation (modafinil,
armodafinil). Of note, these drugs constituted a substantial contribution
to the aforementioned review [33]; however, a recent meta-analysis
reported differences with modafinil or armodafinil in the treatment of
negative symptoms, but the effect size was small [34]. In addition,
another RCT since noted no benefits with modafinil [35].
Recently, lisdexamfetamine (LDX), a pro-drug of amphetamine li-
censed for use in ADHD, has been investigated for its possible treatment
of negative symptoms in schizophrenia. Favorable results were published
based on an open-label, randomized withdrawal phase trial demon-
strating improvement in negative symptoms with LDX and no indication
of positive or negative symptom worsening with its abrupt discontinu-
ation [36]. However, trials have since been terminated.
Anticonvulsants
Reference has been made to these drugs in other reviews of negative symptoms
[13, 18], and, like ECT, these drugs have a long history of augmentation use in
schizophrenia as well as specific subpopulations (e.g., clozapine resistance,
aggression) [37, 38]. In this context, improvement in negative symptoms as one
of a number of outcome measures has been reported, but no controlled studies
have specifically examined anticonvulsants for their utility in negative symp-
toms per se.
Glutamate
This is one of several areas that has garnered considerable attention in recent
years, not only in terms of negative symptoms but positive and cognitive
symptoms as well [39•]. In terms of negative symptoms, numerous com-
pounds, involving both ionotropic and metabotropic receptors, have
been evaluated over the last two decades. Two meta-analyses, not spe-
cific to negative symptoms, suggested a favorable, albeit small, signal
supporting the efficacy of drugs enhancing NMDA receptor function
(e.g., d-serine, sarcosine, N-acetyl-cysteine, D-cycloserine), although the
effect was different between agents [40, 41].
More recently, this line of thinking has spawned interest in other
compounds that are presently being investigated, at least in part, for
their benefits in negative symptoms. While trials continue, results, to
date, have been mixed. Notably, a paper published in the last year
offered ongoing support for d-serine [42], whereas several investigational
compounds have been discontinued during early phase development,
including agents that act through different mechanisms including glycine
transporter 1 (GlyT1) inhibition (e.g., bitopertin) [43] and mGluR2/3-
positive allosteric modulation (e.g., LY2140023) [44]. Further, there are
agents designated as NMDA receptor antagonists that have also been the
subject of investigation [45]. Once again, this speaks to the complexity
of the glutamatergic system and differences between agents working
through different mechanisms of action. Results with these strategies
have as well been equivocal. Disappointing results with bitopertin and
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LY2140023 have led to their discontinuation for this indication [14, 46].
In the case of NMDA receptor antagonists, a meta-analysis examining
amantadine and memantine did not support the utility of these medi-
cations in the treatment of negative symptoms, although the focus was
not on negative symptoms specifically [45]. This said, an RCT published
subsequently and looking at negative symptoms as the primary out-
come reported that memantine led to significant improvement at
8 weeks, with a large effect size (Cohen’s d = 1.5 [95%CI 0.8–2.22])
[47].
Evidence continues to grow supporting a role for glutamate in
processes critical to schizophrenia [48, 49], which may account for
why, in the face of equivocal clinical evidence, efforts continue in
developing new compounds. Suggestions to move the field ahead
include the evaluation of other receptors, intracellular pathways, ill-
ness subtypes as well as stage of illness, and biomarkers/
endophenotypes [39•, 50–54]. Again, though, this work is not con-
fined only to efficacy regarding negative symptoms or, in fact,
schizophrenia.
Acetylcholine
As in the case of glutamatergic agents, the interest in this area is not
specific to negative symptoms; indeed, much of this work has focused
on cognitive symptoms as the primary endpoint. An earlier meta-
analysis evaluating cholinesterase inhibitors in schizophrenia
(rivastigmine, donepezil, galantamine) noted improvement in selected
measures of cognition, but not negative symptoms [55]. A subsequent
meta-analysis also had as its primary focus cognitive symptoms, and as
an aside evaluated both glutamatergic and serotonergic receptors. It did
note an effect on negative symptoms with two agents indicated in the
treatment of Alzheimer’s disease, donepezil, and galantamine [56]; both
share in common action as cholinesterase inhibitors while the latter is
as well an allosteric modulator of nicotine acetylcholine receptors. A
Cochrane review around the same time, and specific to cholinesterase inhibitors
in schizophrenia, also suggested a signal for improvement in negative symptoms
[57]; once more, though, negative symptoms were not the primary outcome.
Further complicating interpretation of results is the need to disentangle the effect
of changes in other domains on negative symptom scores [56], in addition to
other pharmacological effects; for example, galantamine has been reported to
enhance dopamine neurotransmission through its allosteric modulation of
nicotinic acetylcholine receptors [58]. To date, no RCTs have been reported
involving a cholinesterase inhibitor where negative symptoms were the primary
outcome.
Efforts have also included a number of newer α7 nicotinic acetyl-
choline receptor (α7 nAChR) agonists/partial agonists as well as positive
allosteric modulators [59–62]. To this point, though, it is difficult to
evaluate the clinical benefits of this line of investigation. A recent
double-blind trial involving galantamine/CDP-choline did not improve
negative symptoms [63], nor did a recent phase 2 trial with the α7
nAChR agonist, TC-5619 [64]. Added to this is the early discontinuation
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of several other such agents [13]. In addition, there is again the issue of
other mechanisms of action that may contribute to any effect seen; for
example, preclinical evidence has shown that EVP-614, also a α7 nAChR
agonist, increases cortical ACh and glutamate release, and this is true for
dopamine, too [65]. As an aside, increased dopaminergic and norad-
renergic activity has also been reported in association with CPD-choline
administration [66].
Serotonin
The notion that serotonin antagonism may prove useful in the treatment
of negative symptoms gained momentum with the early claims that
atypical antipsychotics, clozapine being the prototype, were superior to
conventional antipsychotics in the treatment of negative symptoms [67].
It was postulated that their concomitant 5-HT2 antagonism played a role
in this which, in turn, led to the development of selective 5-HT2 an-
tagonists that were then investigated further in the treatment of negative
(as well as positive) symptoms (e.g., ritanserin, M100907). While several
RCTs involving ritanserin offered support for this line of investigation
[68, 69], the more recent focus has turned to selective 5-HT3 antagonists
(e.g., ondansetron, tropisetron, granisetron). Several trials specifically
focused on negative symptoms have supported their efficacy [70, 71], as
does a recent meta-analysis although it evaluated their effects on
schizophrenia in general [72].
Sex hormones
Gender differences have been well established in schizophrenia, with
differences reported for age of onset, symptoms, course, and prognosis
[73]. Once more, the work arising from this line of investigation is not
specific to negative symptoms per se, but there is evidence specific to
this topic, including a limited number of RCTs. As a starting point,
various studies have identified relationships between neurosteroids/sex
hormones and negative symptom severity [74–78]. In terms of RCTs,
dehydroepiandrosterone (DHEA), an adrenal hormone involved in the
production of androgens and estrogens, has been reported to improve
negative symptoms [79], as have studies involving pregnenolone [80,
81]. Most recently, two further investigations specifically examining
negative symptoms as part of their primary outcome have been added.
In the first, a combination of pregnenolone and l-theanine over 8 weeks
decreased both negative and anxiety symptoms, the co-primary outcome
measures [82], while in the second the addition of raloxifene, an estro-
gen receptor modulator, decreased negative symptoms over 6 months in
post-menopausal females with schizophrenia and prominent negative
symptoms [83].
Currently, considerable attention is being given to oxytocin, and
there are several recent reviews specific to schizophrenia [84, 85] in
addition to a meta-analysis [86]. While much of the focus is on social
cognition, its potential in the treatment of negative symptoms is
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highlighted in each. As of yet, there is a lack of studies where it has
been specifically evaluated with negative symptoms as the primary focus.
Inflammation-immunology
Kraepelin originally conceptualized schizophrenia as a neuroprogressive disor-
der (i.e., dementia praecox or Bearly dementia^) [87]. More recently, though,
the focus has shifted to schizophrenia as a disorder of neurodevelopment, and
within this framework, there is considerable interest in the role of inflammation
and immune response [88]. Following this line of thinking, it is hypothesized
that agents impacting the inflammatory response may prove useful in treating
symptoms and, perhaps, altering the illness course. Only a limited amount of
this work has been specific to negative symptoms, and in this regard,
minocycline, a broad-spectrum tetracycline antibiotic with neuroprotective
properties mediated through anti-inflammatory, anti-apoptotic, and antioxi-
dant effects [89], has received the greatest attention. A recent meta-analysis
supported its value in the treatment of negative symptoms, although this
domain was not the primary outcome [90]. RCTs, where this is the case, have
beenmixed in their findings. There has been one negative trial [91], and another
where only one domain, avolition (as measured using the SANS), was signifi-
cantly impacted [92]. In contrast, two RCTs have reported positive results, one
involving chronic schizophrenia [93] and one that looked at early-phase
schizophrenia specifically [94]. Two large RCTs, the MINOS Trial and BeneMin,
are currently underway, both focusing on early schizophrenia [95, 96]. Of note,
there is interest in looking at schizophrenia across different symptom domains
and stages of the illness (e.g., treatment resistance) [97], as well as other
conditions where altering immune response may impact outcome (e.g., acute
ischemic stroke) [98].
Compounds reviewed in other sections also have the capacity to act
in a similar fashion. This would include neurosteroids such as preg-
nenolone (sex hormones), as well as compounds that modulate NMDA
receptor-related inflammatory changes (e.g., d-serine, memantine) [42]
(glutamate). Other drugs (e.g., ASA, Cox-2 inhibitors) would as well be
seen as holding promise in this regard [18, 99]. Recent RCTs have been
reported for dextromethorphan [100], methotrexate [101], interferon γ
[102], atorvastatin as well as pravastatin [103], and pioglitazone [104]
in schizophrenia, although none have focused specifically on negative
symptoms. To date, one small RCT evaluating atorvastatin in negative
symptoms has reported benefits [105].
Brain stimulation
This is another line of investigation that currently generates considerable inter-
est reflected in the number of meta-analyses [106–109] and reviews [110]
specific to rTMS and negative symptoms in the last few years. Notably, themeta-
analyses are consistent in the conclusion that rTMS is beneficial, with the effect
size ranging from small and non-significant to as high as 0.80, the variability
reflecting differences in moderators (e.g., study duration, stimulus frequency,
outcome measure, illness duration) [106–109]. Further, a just published RCT
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A meta-analysis of RCT interventions to
December 2013 involving 168 trials
(N=6503 in treatment arm, N=5815 in
placebo arm).
Treatments evaluated included antipsychotics
(AP, first and second generation),
antidepressants (AD), pharmacological
combinations (e.g., AP +AP; AP +AD),
glutamatergic agents, brain stimulation,
and psychological interventions. Some
differences were statistically significant
but none reached threshold for clinical
significance [15••]
Specific somatic interventions
Antipsychotics The introduction of Batypical^ antipsychotics
came with claims of superior efficacy in the
treatment of negative symptoms. This had
been identified with clozapine in trials
evaluating its efficacy in
treatment-resistant schizophrenia
Modest improvement, not clinically
significant, may be observed with
antipsychotic treatment, possibly related
to efficacy on other symptom domains
and/or dopamine Bsparing^. Two recent
meta-analyses, one specific to negative
symptoms, do not support superiority of
the newer antipsychotics [15••, 21]. Going
forward, the notion of developing an agent
that can significantly and simultaneously
impact the different symptom domains of
schizophrenia seems unlikely
Antidepressants This work has been built around
augmentation with SSRIs and, more
recently, the newer classes of
antidepressants that have followed
Only one of three earlier meta-analyses
focused on negative symptoms offered
support for such an approach [24–26].
The fourth and most recent
meta-analysis also did not identify
changes that were clinically significant
[15••]. This said, ADs are used
routinely with APs in schizophrenia
and as they evolve it is likely that new
ADs will be evaluated in negative
symptoms
CNS stimulants This literature has included trials
involving ADHD drugs and, more
recently, drugs indicated in the
treatment of excessive sedation (e.g.,
modafanil). Lisdexamfetamine,
indicated for ADHD, was recently
evaluated for a possible indication in
negative symptoms but this line of
investigation has been terminated
Collectively, this line of investigation has
established that such agents can be used
safely in individuals with psychosis. A
review in 2013 specific to negative
symptoms concluded evidence supports
larger trials be done [33], although a more
recent meta-analysis confined to
modafanil/armodafanil reported only a
small effect size [34]
Anticonvulsants Anticonvulsants are frequently used in
schizophrenia and it is in this context
that a potential effect on negative
symptoms has been reported
This area has not generated a lot of interest.
To date, there are no published RCTs
specifically evaluating this class of
medications in trials focused on negative
symptoms
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Table 1. (Continued)
Topic Literature Comments
Glutamate This line of investigation has garnered a
great deal of research although drawing
conclusions is complicated by different
mechanisms of action. Much of this work is
not confined to negative symptoms per se
Two earlier meta-analyses, not specific to
negative symptoms, suggested these drugs
could be effective [40, 41], and a recent
small RCT (N= 35) involving d-serine
supported this position [42]. However,
trials with agents working through other
mechanisms (e.g., bitopertin, LY2140023)
have been terminated for this indication. A
meta-analysis examining NMDA antagonists
(8 studies, N=406) did not support their use
in negative symptoms [45], but a small RCT
(N=40) since reported a large effect size
[47]. The recently published meta-analysis
looking at numerous treatments did not
report clinically significant results for
glutamatergic agents as a class [15••].
Despite these mixed results, work along
these lines is likely to continue
Acetylcholine This focus has also garnered considerable
interest in recent years, but once again the
focus is not specific to negative symptoms.
The research can be divided into work
involving cholinesterase inhibitors (e.g.,
donepezil) and a newer group of α7 nAChR
agonists/partial agonists as well as
positive allosteric modulators
Three meta-analyses examining the
cholinesterase inhibitors, but not specific
to negative symptoms, have suggested
potential benefits [55–57] but no such
RCTs have been published as of yet. Taken
together, results with the newer α7 nAChR
agents have not been favorable, and it is
presently unclear if efforts specific to
negative symptoms will be continued
Serotonin Earlier work involving selective 5-HT2
antagonists (e.g., ritanserin) has given
way to research focused on 5-HT3 agents
(e.g., ondansetron)
A recent meta-analysis looking at different
domains in schizophrenia has offered
support for this approach [72], as have
several RCTs specific to negative symptoms
[70, 71]
Sex Hormones Support for this line of investigation arises
from work identifying a relationship
between neurosteroids/sex hormones and
negative symptom severity, in addition to
treatment trials
A small number of trials specific to negative
symptoms, and utilizing different agents
(DHEA, pregnenolone, raloxifene) have
been carried out, with favorable results
[80–83]. Oxytocin is receiving
considerable attention at present,
particularly in terms of measures of social
cognition. A recent meta-analysis
indicated it may have a role to play in
schizophrenia and alluded to some
evidence regarding its value in negative
symptoms [86]. As of yet, though, specific
trials of this sort have not been published
Inflammation/Immunology This particular research aligns closely with the
shift in focus to neurodevelopmental
Much of the work to date has involved
minocycline, with RCTs specific to negative
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indicated that response with active treatment is sustained over a 24-week
follow-up [111]. However, another recently published RCT (n=175) failed to
establish a beneficial effect with active versus sham rTMS [112••]. Given the
many moderators that can impact outcome, it is difficult to reconcile these
findings with the numerous earlier reports and meta-analyses, but the most
recent investigation is by far the largest in terms of sample size.
Going forward, there is interest in deep rTMS and its impact on such features
as negative symptoms in schizophrenia [113], but it remains for future inves-
tigations to address this line of investigation. Transdirect current stimulation
(tDCS) is being pursued in the treatment of schizophrenia, and a recent review
has concluded that it may prove useful for negative symptoms [114]; to date,
however, there is only one small RCT published, although results are favorable
regarding negative symptoms [115].
Other forms of brain stimulation remain of interest, but as of yet have been
the subject of much less investigation. Electroconvulsive therapy (ECT) has a
long history as a treatment in schizophrenia, although at this point is largely
confined to augmentation in TRS; in fact, it is amongst the recommended
options in the face of partial clozapine response (i.e., ultra-resistant schizo-
phrenia) [116]. While TRS is generally characterized by positive symptoms, a
small body of literature has recently reported success in themanagement of TRS
Table 1. (Continued)
Topic Literature Comments
models of schizophrenia and, like other
areas discussed, is not specific to negative
symptoms or, in fact, schizophrenia
symptoms providing mixed results
[91–94]. Compounds reviewed under other
categories here (e.g., d-serine
[Glutamate); pregnenolone [Sex
Hormones]) may, at least in part, establish
their response through these mechanisms
as well. Larger trials with minocycline are
underway [95, 96], and it can be expected
that other agents will be evaluated in trials
where negative symptoms are the primary
outcome
Brain Stimulation Brain stimulation, including both ECT and
rTMS, has a history in refractory forms of
schizophrenia (e.g., TRS, refractory
hallucinations) although considerable
work with rTMS is now focused on negative
symptoms
While earlier meta-analyses supported the
efficacy of rTMS in negative symptoms
[106–109], the largest trial to date, just
published, failed to find benefits [112••].
A number of identified moderators of
response complicate comparison across
studies, and newer techniques (e.g., dTCS,
DBS) have little or no data. Given the
evidence to date, conflicting as it is,
further studies of this sort are likely to
continue
AD antidepressant, ADHD attention deficit hyperactivity disorder, AP antipsychotic, DBS deep brain stimulation, dTCS direct transcranial
stimulation, 5HT serotonin, nAChR nicotinic acetylcholine receptor, NMDA N-methyl-D-aspartate, RCT randomized controlled trial, rTMS repetitive
transcranial magnetic stimulation, SSRI selective serotonin reuptake inhibitor
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with prominent negative symptoms [117–119]. However, these preliminary
results have not been corroborated by RCTs.
Repeated vagus nerve stimulation (rVNS) has been identified as useful in
other medical and psychiatric conditions (e.g., epilepsy, depression), and a
recent randomized, sham controlled and double-blind study evaluated its
efficacy in schizophrenia, although efficacy was not established across any
outcomemeasure, including negative symptoms [120]. Deep brain stimulation
(DBS) has also found a role in the treatment of differentmedical and psychiatric
conditions, and while there is interest and a rationale for use in negative
symptoms [121], no such studies have been published as of yet.
Conclusions
Table 1 summarizes the literature discussed. As concluded in the recently
published meta-analysis [15••], there is insufficient evidence at present to
support a specific treatment for negative symptoms. This is despite a tremen-
dous increase in interest in the topic, as well as studies where negative symp-
toms are the identified primary outcome.
A number of factors may contribute to the lack of success to date. Diagnos-
tically, it is difficult distinguishing primary from secondary negative symptoms,
just as it is a challenge differentiating negative symptoms from other psychiatric
diagnoses such as depression. Our understanding regarding underlying patho-
physiological processes is notwell established, resulting in strategies for treatment
that are, at best, speculative. This is perhaps best captured by the numerous trials
that choose to assessmultiple symptomdomains rather than focusing specifically
on negative symptoms. From a conceptual standpoint, the very definition of
negative symptoms represents a work in progress, and it has been demonstrated
that outcomes can be influenced by the measures employed [16, 122]. More
recently, guidelines have been forwarded regarding study trial design [123•], but,
in fact, much of the work to this point falls short of these standards. It is now
common to isolate different components under the framework of negative
symptoms [6], but this strategy is in its earliest stages and it is unclear how these
may differentially respond to treatment. We continue to seek biomarkers and/or
endophenotypes that may not only improve diagnosis but, in addition, advance
the field in clinical subtyping; already, different trajectories have been reported
[124] but this work too is in its earliest stages. It has been established that negative
symptoms predate the onset of positive symptoms, and there is speculation that
aberrations occurring during neurodevelopment are responsible. This under-
scores the importance of timing of interventions, and expectations regarding the
success of treatments that are implemented later in the illness course. Indeed, it is
possible that effective treatments await that time when we can reliably identify
those who will go on to develop schizophrenia, which would also permit
interventions well in advance of when diagnosis occurs, that is when psychotic
features are evident for the first time. Where benefits have been recorded to this
point, the reported effect size is often not of a magnitude to be clinically
significant [15••]. Finally, there is evidence that non-biological factorsmay play a
role [125, 126], which raises questions as to the limitations of somatic interven-
tions and the need to investigate their benefits in combination with non-
biological strategies.
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Future drug development in the field of schizophrenia clearly identifies
negative symptoms as an important unmet need [127]. This is undoubtedly
driven, at least in part, by evidence that negative symptoms play a critical
role in the functional decline observed in many individuals with schizo-
phrenia, a decline that is not necessarily addressed with adequate control of
positive symptoms. What is less clear, however, is what lines of investiga-
tion hold promise of success or, in fact, whether effective strategies can be
developed until we are able to reliably diagnose schizophrenia and imple-
ment treatments earlier in the illness’ evolution.
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